Beta-2-Microglobulin (Beta-2-M), Serum
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Prognosis assessment of multiple myeloma
Evaluation of renal tubular disorders
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
See Laboratory Screening Tests for Suspected Multiple Myeloma in Special Instructions.
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Microglobulin, Beta 2
Microglobulin, Beta 2
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Preferred: Red top
Acceptable: Serum gel
Specimen Volume: 1 mL
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Mild OK; Gross OK
Mild OK; Gross reject
Mild OK; Gross OK
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
|Serum||Refrigerated (preferred)||14 days|
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Beta-2-microglobulin (beta-2-M) is a small membrane protein (11,800 Dalton) associated with the heavy chains of class I major histocompatibility complex proteins and is, therefore, on the surface of all nucleated cells. The small size allows beta-2-M to pass through the glomerular membrane, but it is almost completely reabsorbed in the proximal tubules.
Serum beta-2-M levels are elevated in diseases associated with increased cell turnover. Levels are also elevated in several benign conditions such as chronic inflammation, liver disease, renal dysfunction, some acute viral infections, and a number of malignancies, especially hematologic malignancies associated with the B-lymphocyte lineage.
In multiple myeloma, beta-2-M is a powerful prognostic factor and values <4 mcg/mL are considered a good prognostic factor.
In renal tubular disease, serum levels are low and urine levels are high. Although urine beta-2-M has been used to assess tubular dysfunction, it is not stable in urine below pH 5.5.
See Diagnosis and Monitoring of Multiple Myeloma in Publications. Also see Laboratory Screening Tests for Suspected Multiple Myeloma in Special Instructions.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Serum beta-2-microglobulin (beta-2-M) <4 mcg/mL is a good prognostic factor in patients with multiple myeloma. In a study of pretreatment serum beta-2-M levels in 100 patients with myeloma it was reported that the median survival of patients with values >4 mcg/mL was 12 months, whereas median survival for patients with values <4 mcg/mL was 43 months.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Bataille R, Magub M, Grenier J, et al: Serum beta-2-microglobulin in multiple myeloma: Relation to presenting features and clinical status. Eur J Cancer Clin Oncol 1982;18:59-66
2. Garewal H, Durie BG, Kyle RA, et al: Serum beta-2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J Clin Oncol 1984;2:51-57
3. Norfolk D, Child JA, Cooper EH, et al: Serum beta-2-microglobulin in myelomatosis: potential value in stratification and monitoring. Br J Cancer 1980;42:510-550
4. Dolan MJ, Lucey DR, Hendrix CW, et al: Early markers of HIV infection and subclinical disease progression. Vaccine 1993;11:548-551
5. Karlsson FA, Wibell L, Evrin PE: Beta-2-microglobulin in clinical medicine. Scand J Clin Lab Invest 1986;154:27-37
6. Greipp PR, Katzmann JA, O'Fallon WM, Kyle RA: Value of beta-2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988;72:219-223
Method Description Describes how the test is performed and provides a method-specific reference
Concentrations of beta-2-microglobulin are determined by nephelometry.(Instruction manual: Siemens Nephelometer II Operations. Siemens, Inc., Newark, DE)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Saturday; 3 p.m.
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Same day/1 day
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
|Result ID||Reporting Name||LOINC Code|